Opportunity to Partner Novel VHH Multi-Specific Antibodies Targeted at Solid and Hematologic Tumors

Our client, Starmab Biomed Inc (“Starmab” or the “Company”), is a US/China-based biotech company headquartered at Beijing Zhongguancun Life Science Park, with R&D facilities in Beijing and California.

We would be pleased to arrange a Zoom meeting with Starmab’s management team to discuss their platform and pipeline and answer any questions.

Starmab has developed a proprietary VHH multi-specific antibody discovery and production platform. VHH antibodies, also known as single-domain antibodies, are structurally distinct from traditional antibodies due to their single-chain, single-domain nature, retaining only the antigen-binding region of the heavy chain domain. Their small molecular weight (15 kDa) enables them  to make multi-specific antibody to  target multiple antigens with high specificity and flexibility.

Key Assets

1. SM2275

   Best-in-class T-cell engager targeting EGFR/PD-L1/CD28/HSA for solid tumors. An IND submission is planned for late Q1 2025. SM2275's unique features include:

   • Modular and linker design enabling flexible antibody construction tailored to clinical needs.

   • Dual tumor-antigen targeting for enhanced specificity.

   • Dual tumor-target-dependent CD28 activation to minimize systemic immune toxicity.

   • Avidity-enhanced PD-L1 blockade for TME-restricted T-cell activation.

   • CD28 and PD-L1 signaling synergy improving anti-tumor efficacy.

   • HSA-binding domain optimizing in vivo half-life.

   
   

2. SM3321

   
   

   Multitargeted VHH construct targeting CD33/CD47/HSA/CD16A for acute myeloid leukemia (AML). Currently in a Phase 1 study in China, SM3321 is positioned as a treatment for relapsed/refractory AML post-bone marrow transplant (r/r AML PMT). Early results from this study show one complete response and one partial response among two patients. Starmab estimates the cost to complete this 30-patient trial at $3 million.

   
   

Partnership Opportunity

Starmab has engaged The Sage Group to identify a global partner for SM2275 and SM3321.